NRGN and Alzheimer disease: In clinical trial, COG0201 (SHINE—NCT03507790), an interim analysis of CSF biomarker data did not provide insight into Nrgn and Syt1, but the trial identified pharmacodynamic biomarkers linked to pathway engagement (CT1812’s mechanism of action), disease modification biomarkers associated with favourable cognitive outcomes in the CT1812 treatment group, and disease modification markers which are altered in AD but normalized with CT1812 treatment [18].